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Abstract
The targeted delivery of therapeutics to the tumor site is highly desirable in cancer treatment, because it is capable of minimizing
collateral damage. Herein, we report the synthesis of a nanoplatform, which is composed of a 15 ± 1 nm diameter core/shell
Fe/Fe3O4 magnetic nanoparticles (MNPs) and the topoisomerase I blocker SN38 bound to the surface of the MNPs via a
carboxylesterase cleavable linker. This nanoplatform demonstrated high heating ability (SAR = 522 ± 40 W/g) in an AC-magnetic
field. For the purpose of targeted delivery, this nanoplatform was loaded into tumor-homing double-stable RAW264.7 cells (mouse
monocyte/macrophage-like cells (Mo/Ma)), which have been engineered to express intracellular carboxylesterase (InCE) upon
addition of doxycycline by a Tet-On Advanced system. The nanoplatform was taken up efficiently by these tumor-homing cells.
They showed low toxicity even at high nanoplatform concentration. SN38 was released successfully by switching on the Tet-On
Advanced system. We have demonstrated that this nanoplatform can be potentially used for thermochemotherapy. We will be able
to achieve the following goals: (1) Specifically deliver the SN38 prodrug and magnetic nanoparticles to the cancer site as the
payload of tumor-homing double-stable RAW264.7 cells; (2) Release of chemotherapeutic SN38 at the cancer site by means of the
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self-containing Tet-On Advanced system; (3) Provide localized magnetic hyperthermia to enhance the cancer treatment, both by
killing cancer cells through magnetic heating and by activating the immune system.
Introduction
Irinotecan (CPT-11) is a potent chemotherapeutic prodrug
against various types of cancer, such as colorectal, lung, and
ovarian cancer [1-5]. It is converted by carboxylesterase
(predominantly in the liver) to its biologically active metabolite
SN38 (7-ethyl-10-hydroxycamptothecin) [6-9]. Although
CPT-11 had been approved as an anticancer agent by the US
Food and Drug Administration (FDA) in 1997, the use of this
prodrug is limited due to the low conversion rate (only 2–8%)
of the administered dose into active SN38 in patients [10,11]. In
addition, the conversion of CPT-11 into SN38 shows high inter-
patient variability because of the genetically different activity of
carboxylesterase among individual patients [12,13]. Moreover,
severe side effects, such as life-threatening diarrhea and
neutropenia, have been observed [14,15]. SN38 is a topoiso-
merase I inhibitor, and it has demonstrated 100- to 1000-fold
more cytotoxicity against various cancer cells in vitro than
CPT-11 [6]. Despite the excellent anticancer potential, SN38
has not been used as an anticancer drug directly in humans due
to its inherent poor solubility in any pharmaceutically accept-
able media (solubility in water <5 µg/mL). To overcome this
disadvantage of SN38, two major basic strategies have been
developed. The first strategy is to directly introduce biocompat-
ible hydrophilic functional groups to SN38 through chemical
modification. A 40 kDa polyethylene glycol has been linked to
the SN38 [16]. The highly water-soluble PEGylated SN38
(EZN-2208) demonstrated both drastic enhancement of its
circulating half-life and preferential accumulation in solid
tumors [17-19]. SN38 conjugated to a cationic peptide (Vecto-
cell) by an esterase cleavable linker has been reported. The
conjugate (DTS-108) is highly soluble in water and liberated
significantly higher levels of free SN38 than CPT-11 did in a
dog model [20]. An alternate strategy is to use delivery vehi-
cles that can incorporate SN38 by chemical conjugation or
physical entrapment. Polymeric micelles, liposomes and ther-
mally sensitive polymer-based nanoparticles, as well as multi-
armed-PEG-functionalized nanographene oxide, have been used
as carriers for the delivery of SN38 into biological systems [21-
26]. SN38-loaded polymeric micelles (NK012) have been used
in preclinical and clinical studies against various types of
cancer. Specific accumulation of this formulation to the tumor
site by the EPR effect (enhanced permeation and retention), and
sustained release of SN38 in tumor tissue have been observed
[22]. Liposome encapsulation of SN38 (LE-SN38) enhances the
solubility of SN38 and provides protection from rapid drug
degradation. Increased cytotoxicity against various tumor cell
lines and better therapeutic efficacy in xenograft mouse models,
as compared to CPT-11, have been reported. Recently, we
described a self-contained enzyme-activating prodrug
cytotherapy for preclinical melanoma [27]. CPT-11 was loaded
into double-stable RAW264.7 monocyte/macrophage-like cells
(Mo/Ma) containing a Tet-On Advanced system for intracel-
lular carboxylesterase (InCE) expression. The double-stable
Mo/Ma homed to the lung melanoma within one day and
successfully delivered the prodrug-activating enzyme/prodrug
package to the tumors. Significantly reduced tumor weights and
numbers were observed after activation of InCE. We also
showed that these cells can carry the SN38–dextran irinotecan-
like prodrug to the tumor site, and, upon activation of a previ-
ously silenced gene with doxycycline, significantly increased
survival in a murine pancreatic cancer model in mice was
observed [28]. Hyperthermia uses heat to kill cancer cells [29].
Numerous clinical trials have demonstrated that the combina-
tion of hyperthermia with radiation therapy and chemotherapy
can greatly improve the efficacy of cancer treatment [30,31].
Ultrasmall magnetic nanoparticles generate heat efficiently in
an alternating magnetic field (AMF). Due to their superior prop-
erties, such as negligible or low toxicity, biocompatibility, and
potential for targeted accumulation at the tumor site, ultra-small
magnetic nanoparticles are the prime candidates for application
in magnetic hyperthermia [32-34]. We have developed a
magnetic core/shell Fe/Fe3O4 nanoparticle platform, which can
generate substantial heat within a magnetic field with low
strength and frequency. Attenuation of mouse melanomas after
AMF treatment was observed with both ligand-directed and
cell-based cancer-specific delivery of magnetic nanoparticles
[35,36]. When the nanoparticles were transported by
RAW264.7 cells (monocyte/macrophage like cells) to the tumor
site, survival of black mice bearing metastatic pancreatic tumors
was increased by 31% after AMF treatment, compared to a
nontreated control group [37].
In this report, we describe the synthesis of a prodrug combining
SN38 and stealth core/shell Fe/Fe3O4 magnetic nanoparticles.
The nanoparticles are functionalized with dopamine–oligo-
ethylene glycol ligands, which make the nanoparticles both
water-soluble and biocompatible. SN38 is covalently bound to
the “tip” of the ligands by means of a carboxylesterase-cleav-
able linker. The nanoplatform can be loaded into double-stable
RAW264.7 monocyte/macrophage-like cells (Mo/Ma)
containing a Tet-On Advanced system for intracellular
carboxylesterase (InCE) expression. Upon addition of doxycy-
cline, SN38 is released from the nanoparticles, as evidenced by
HPLC analysis. The nanoplatform shows efficient heating
ability in an alternating magnetic field. This system can be
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Scheme 1: Preparation of core/shell Fe/Fe3O4 magnetic nanoparticles (MNPs).
potentially used as a multipurpose anticancer reagent for trig-
gered thermochemotherapy. Delivery within Mo/Ma cells is
capable of evading the reticuloendothelial system. Mo/Ma cells
are known to integrate with the tumor tissue [28]. The acti-
vation of SN38 by InCE expression can be precisely timed.
Localized hyperthermia has the potential to work in synergy
with chemotherapy, especially because both hyperthermia and
the activation of SN38 can be precisely and independently
timed. Furthermore, hyperthermia is known to activate the
immune system if the correct temperature is chosen [29].
Experimental
Materials
SN38 was purchased from Qventas (Newark, DE). Dopamine
hydrochloride, Boc anhydride, benzyl bromide, trifluoroacetic
acid,  succinic acid anhydride, tetraethylene glycol,
4-piperidinecarboxylic acid, EDC, DMAP, CDI, Fe(CO)5,
oleylamine, ODE, hexadecylamine, fetal bovine serum (FBS),
neocuproine, ascorbic acid, ammonium acetate, and concen-
trated hydrochloric acid (HCl) were purchased from Sigma-
Aldrich (St. Louis, MO). RAW264.7 mouse monocyte/
macrophage (Mo/Ma) cells were purchased from ATCC
(Manassas, VA). RPMI, Geneticin (G418), hygromycin and
penicillin-streptomycin were purchased from Invitrogen
(Carlsbad, CA). Thiazolyl blue and sodium dodecyl sulfate
were purchased from Fisher Scientific (Pittsburgh, PA).
Ferrozine was purchased from Hach (Loveland, CO).
Synthesis of core/shell Fe/Fe3O4 magnetic nanopar-
ticles (MNPs)
The core/shell Fe/Fe3O4 magnetic nanoparticles were synthe-
sized by extensive modification of a literature procedure origi-
nally described by Lacroix et al. [38] (Scheme 1). Thermal
decomposition of iron pentacarbonyl (Fe(CO)5) in octadecene
(ODE) under argon in the presence of oleylamine and hexade-
cylammonium chloride (HAD·HCl) at 180 °C gave highly crys-
talline iron(0) nanoparticles. When these nanoparticles were
exposed to air at room temperature, a thin layer of Fe3O4
formed due to the oxidation of the nanoparticle surface, thus,
core/shell Fe/Fe3O4 nanoparticles were constructed. The intro-
duction of the Fe3O4 shell provides easy surface functionaliza-
tion of the core/shell Fe/Fe3O4 nanoparticles. The obtained
nanoparticles were washed with hexane and ethanol, collected
by centrifugation, and dried under high vacuum for further use
in this study.
Synthesis of a hydrophilic dopamine-anchored
InCE-cleavable linker between SN38 and Fe/Fe3O4
magnetic nanoparticles
The synthesis of a hydrophilic dopamine-anchored InCE-cleav-
able linker between SN38 and Fe/Fe3O4 nanoparticles was
achieved in a 10-step reaction procedure, as described in
Scheme 2. Briefly, after selective protection of the hydroxyl
groups of dopamine 1 with benzyl bromide, the free amine
group was reacted with succinic acid anhydride to form com-
pound 5. Tetraethylene glycol reacted with compound 5 in an
EDC-coupling reaction to give compound 6. Deprotection of
the hydroxyl groups by Pd/C-catalyzed hydrogenation yielded
compound 7, which was used as ligand I to enhance the water
solubility of the magnetic nanoparticles (MNPs). A piperidine
moiety was introduced by reacting compound 6 with com-
pound 9 to afford compound 10. After removing the Fmoc
group, compound 11 reacted with 10-OH of SN38 in the pres-
ence of CDI to give compound 12. The final product 13 was
obtained after deprotection of the hydroxyl groups by Pd/C-
catalyzed hydrogenation, and was used as ligand II to incorpo-
rate SN38 to the MNPs. Compound 13 was fully characterized
with 1H NMR, 13C NMR, and mass spectrometry.
Loading SN38 to Fe/Fe3O4 magnetic nanoparticles
(MNPs)
Loading of SN38 to core/shell Fe/Fe3O4 magnetic nanoparti-
cles was achieved by ligand exchange (chemisorptions) due to
the much higher affinity of dopamine for the Fe3O4 surface
compared to oleylamine [39-45]. A solution of compound 7 and
compound 13 in DMF with a molar ratio of 10/1 was added to a
dispersion of freshly synthesized Fe/Fe3O4 nanoparticles in
hexane. After sonication for 5 min all the nanoparticles precipi-
tated out, and the supernatant became a clear solution. After
decanting of the supernatant, the nanoparticles were washed
with hexane, DMF and ethanol to remove the free ligands. The
obtained nanoparticles were dried in high vacuum.
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Scheme 2: Functionalization of SN38.
Characterization of the Fe/Fe3O4 magnetic
nanoparticles and the organic ligands
The morphology of the core/shell Fe/Fe3O4 magnetic nanoparti-
cles loaded with or without SN38 was characterized by trans-
mission electron microscopy (TEM). The TEM samples were
prepared by immersing carbon-coated 200-mesh copper grids
into a solution of drug-free or SN38-loaded MNPs followed by
washing of the grids with dropwise chloroform and drying
overnight in a desiccator. The dried grids were analyzed with a
Philips CM100 microscope operated at 100 kV. High-resolu-
tion TEM was recorded on FEI Tecnai F20XT, 200 kV; FEI,
Hilsboro, OR. Powder X-ray diffraction (XRD) patterns were
obtained on a Bruker D8 X-ray diffractometer with Cu Kα radi-
ation. The hydrodynamic diameter and the zeta potential of the
MNPs were measured on a ZetaPALS zeta potential analyzer
(Brookhaven Instruments Corporation) by hydrodynamic light
scattering and laser Doppler electrophoresis. The 1H NMR and
13C NMR were obtained on a Varian Unity Plus (400 MHz)
NMR spectrometer with deuterated chloroform or DMSO as
solvents and TMS as the internal standard. ESI–MS spectra
were acquired on an API4000 (Applied Biosystems, Foster
City, CA) triple quadrupole mass spectrometer with electro-
spray ionization (ESI). Fluorescence measurements of free
SN38 and SN38-loaded MNPs were performed on a Fluoro
Max-2 instrument (HORIBA Jobin Yvon Company). The
samples were excited at λ = 380 nm. UV–vis absorption
analysis was carried out on a Cary 500 UV–vis–NIR spec-
trophotometer. The SN38 loading on the magnetic nanoparti-
Beilstein J. Nanotechnol. 2012, 3, 444–455.
448
cles was determined by HPLC. The HPLC system consists of a
Waters 1525 binary HPLC pump, Waters 1500 column heater,
and Waters 2998 photodiode array detector. The Freeze 2
chromatographic software was used for data acquisition and
processing. The quantification of SN38 was achieved on an
Agilent Eclipse XDB-C8 (4.6 × 150 mm, 5 μm) analytical
column by using a mobile phase consisting of a water and
methanol gradient from 60/40 to 5/95 in 20 min with a total
flow of 1 mL/min. SN38 was detected at an UV wavelength of
380 nm, and quantitatively determined by an internal calibra-
tion method with anthracene as the internal standard.
Alternating magnetic field (AMF) heating of the
MNPs
For the measurement of the heating effect, an induction heater
(Superior Induction Company, Pasadena, CA) was used. The
heater contains a copper coil, one inch in diameter with four
turns, and is continuously cooled with cold water. The heater
was operated with 5 kA/m field amplitude and 366 kHz
frequency. SN38-loaded Fe/Fe3O4 nanoparticles (MNP-SN38)
were dispersed in water, and were subjected to the alternating
magnetic field for 5 min. To measure the temperature change, a
fiber optic probe (Neoptix, Quebec, Canada) was used.
Cell culture
RAW264.7 cells (mouse monocyte/macrophage-like cells,
Mo/Ma) were cloned with the rabbit carboxylesterase (InCE)
gene with Tet-On system and made double stable. Generation of
the double-stable cells inducible for InCE (double-stable
Mo/Ma) was described in an earlier paper [27]. Double-stable
Mo/Ma were cultured in the RPMI medium containing 10%
fetal bovine serum (Sigma) in a 37 °C humidified incubator
with 5% CO2, with 100 µg/mL Geneticin (G418) and 100 µg/
mL hygromycin added to preserve stable transfection.
Loading Mo/Ma with nanoparticles and determin-
ation of iron loading in Mo/Ma cells
To determine the loading of nanoparticles, Mo/Ma were plated
in a six-well plate at a density of 300,000 cm−2, and incubated
overnight at 37 °C to become 70% confluent. The next day, the
medium was removed and 0 to 320 µg/mL of SN38-loaded
Fe/Fe3O4 nanoparticles in fresh medium was added. After 24 h,
the medium was removed; the cells were washed with 1× PBS
three times, and stained with Prussian blue and counter stained
by nuclear fast red to confirm that the loaded nanoparticles were
iron/iron oxide nanoparticles.
Flow cytometry
Flow cytometry was used to determine the percentage of cells
loaded with MNP. The cells were plated in six-well plates at a
density of 300,000 cm−2 and allowed to attach overnight. The
next day, the cells reached 70% confluence. They were then in-
cubated with 0, 20, 40, 80, 160, 320 µg/mL of SN38-loaded
Fe/Fe3O4 nanoparticles in fresh medium and incubated
overnight. After taking up the nanoparticles, the cells were
washed three times with 1× PBS and lifted by scraping. MNP
loaded cells were analyzed by flow cytometry. Side scatter was
used to determine the loading of the nanoparticles in the cells
and compared to the side scatter of control cells. 10,000 cells
were counted and analyzed. This procedure was repeated three
times. Data were analyzed by using Cytosoft software (Guava
Easycyte Plus System, Millipore Corporation, MA).
MTT Assay
The MTT assay [46] was carried out to determine the toxicity of
NMP-SN38 on Mo/Ma. 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) was dissolved in PBS at
5 mg/mL to prepare the MTT reagent solution. MTT solubiliza-
tion buffer was prepared by dissolving 10% (w/v) sodium dode-
cylsulfate and 0.10 M HCl in water. To assay the cell viability,
MTT reagent solution 1:10 (v/v, reagent solution/cell medium)
was added to the cells and incubated at 37 °C for 4 h. After
incubation, the MTT solution in buffer (1:1, medium/buffer)
was added to the medium, incubated overnight, and the
absorbance at 550 nm and 690 nm, as background absorbance,
was measured by using a plate reader (spectraMAX 190, Mole-
cular Device, Sunnyvale, California).
Ferrozine Assay
The iron content of the nanoparticles and the nanoparticle-
loaded cells was determined by using the ferrozine assay [47].
SN38-loaded Fe/Fe3O4 nanoparticles (MNP-SN38) were loaded
into double-stable Mo/Ma with 0, 20, 40, 80, 160, 320 µg/mL,
as described before. The incubation time was 24 h. Then the
cells were lifted, suspended in 2.0 mL of distilled water and
lysed by using sonifire (sonicator) for 30 sec. Cell debris was
removed by centrifugation at 1000 RPM for 3 min. MNP-SN38
were also suspended in 2 mL of distilled water for comparison
purposes. HCl (0.5 mL; 1.5 M) and 0.20 mL of ascorbic acid
(2.0 M) were added to each sample and incubated at 70 °C for 1
h. The ferrozine reagent solution was prepared as follows: 6.5
mM ferrozine, 13.1 mM neocuproine, 2.0 mM ascorbic acid and
5.0 M ammonium acetate in distilled water. After the incuba-
tion period, 0.20 mL of ferrozine reagent solution was added.
The complexation of iron(II) was complete within 30 min at
room temperature, as indicated by UV–vis absorption spectrom-
etry. The absorbance was recorded at 562 nm. Iron solutions at
0, 0.1, 0.2, 0.5, 1.0, 2.0, and 5.0 µg/mL were prepared in
distilled water by using 0.125 N ferrous ammonium sulfate.
The ferrozine assay was then used to obtain a standard
curve and to determine the iron content in the Fe/Fe3O4
nanoparticles.
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Figure 1: TEM of the core/shell Fe/Fe3O4 nanoparticles: (a) freshly synthesized MNPs; (b) MNP-SN38; (c) HRTEM of MNP; (d) HRTEM of MNP-
SN38. (Note that the dark spots in a and b result from the presence of multiple layers.)
Results and Discussion
Introducing hydrophilic dopamine to SN38
Dopamine has been reported as a robust anchor to immobilize
functional groups on the surface of iron oxide nanoparticles
[39-45]. Introducing polyethylene glycol to the dopamine
anchor can greatly improve both the solubility and biocompati-
bility of iron oxide nanoparticles [48,49]. We have demon-
strated in our previous papers that dopamine linked with simple
tetraethylene glycol could sufficiently enhance the solubility
and biocompatibility of core/shell Fe/Fe3O4 nanoparticles
[35,37]. Here, we have conjugated the anticancer agent
SN38 to the dopamine–tetraethylene glycol moiety via a
carboxylesterase-cleavable linker, in analogy to the biochem-
ical activation of CPT-11 [11]. We expect that through this
design, two goals can be achieved:
(1) The hydrophilic dopamine functionalized SN38 prodrug is
less toxic than SN38 itself, because structurally it is more like
CPT-11.
(2) The SN38-prodrug can be immobilized on the water-soluble
core/shell Fe/Fe3O4 magnetic nanoparticles through the
dopamine anchor, and then the whole nanoplatform is loaded on
double-stable monocyte/macrophage-like cells to specifically
target the tumor, and release SN38 at the tumor site by the
Tet-On Advanced system.
It is noteworthy that the hydrophilicity of the SN38 prodrug
(log P(13) = 0.55) is higher than that for the tetraethylene glycol
stealth ligand (log P(7) = −0.51), which is the reason why we
have selected the molar ratio of 1/10 for 13 and 7 at the surface
of the Fe/Fe3O4 nanoparticles. The pharmacologically active
lactone form of SN38 is distinctly less hydrophilic (log P =
0.89). It can associate with cell membranes and diffuse into
cells. Therefore it is very important that SN38 will be activated
“on site” to minimize collateral damage. The construction of the
nanoparticle-binding SN38 prodrug was achieved in a 10-stage
synthesis with overall 32% yield. The final product was fully
characterized by 1H NMR, 13C NMR, and mass spectrometry.
Characterization of the nanoparticles
Figure 1a shows a low-resolution transmission electron micro-
scope (TEM) image of the nanoparticles. The image reveals that
the nanoparticles are roughly spherical, and a core/shell struc-
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ture of the nanoparticles is clearly demonstrated. The average
Fe(0) core diameter is 12 ± 0.5 nm and the thickness of the
Fe3O4 shell is around 1.5 ± 0.5 nm. Exchange of the oleyl-
amine/HDA ligands with the dopamine-based hydrophilic
ligands 7 and 13 effectively renders the nanoparticle water-
soluble. Figure 1b shows the TEM image of SN38-loaded
Fe/Fe3O4 nanoparticles from PBS (pH 7.4) dispersion.
Comparing the two TEM images, negligible changes on both,
shape and size of the nanoparticles could be discerned. As
revealed by high-resolution transmission electron microscopy
(HRTEM) (Figure 1c and Figure 1d), the SN38 loaded
Fe/Fe3O4 nanoparticles are crystalline with distinct lattice
fringes.
Figure 2 shows the powder X-ray diffraction (XRD) pattern of
SN38-loaded Fe/Fe3O4 magnetic nanoparticles. Highly crys-
talline structures were confirmed. The XRD peaks at 2θ = 44.7
and 65.1° correspond to (110) and (200) lattice-plane spacings
of bcc-Fe [38,50]. No Fe3O4 diffraction peaks are observed due
to their small crystal domains. It has been found that this
nanoplatform is very robust against oxidation. The XRD
patterns remained virtually unchanged even after the MNP-
SN38 was exposed to air for two weeks at room temperature.
Figure 2: Powder XRD patterns of MNP-SN38.
The SN38-loaded Fe/Fe3O4 magnetic nanoparticles can be
easily dispersed in pH 7.4 PBS buffer (up to 30 mg/mL). The
dynamic light scattering (DLS) shows that the hydrodynamic
diameter of the nanoparticles in water is about 95 nm, indi-
cating that some level of aggregation occurred in the aqueous
media, but overall the nanoparticles are monodisperse with a
narrow size distribution (polydispersity <0.20) (Supporting
Information File 1, Figure S1). Since the MNP-SN38 platform
will be loaded on Mo/Ma cells for target delivery, the low-level
aggregation of the MNP-SN38 will not cause such a problem as
direct IV injection does. The zeta potential measurement carried
out in deionized water at pH 7 demonstrates that the nanoparti-
cles bear positive charges on the surface, with a value of
27.8 mV (Supporting Information File 1, Figure S2). This value
is close to the threshold of 30 mV, which is considered as stable
for nanoparticles [51]. Fluorescence spectra of MNP-SN38 and
SN38 released from the same amount of MNP-SN38 were
presented in Figure 3. Significant fluorescence quenching was
observed for SN38 tethered on the surface of Fe/Fe3O4
magnetic nanoparticles, indicating the close proximity of SN38
to the magnetic nanoparticle. We also performed UV–vis char-
acterization of the MNP-SN38 in PBS solution, but the absorp-
tion of SN38 was not observed due to overlapping with the
broad MNP absorption.
Figure 3: Fluorescence spectra of MNP-SN38 and free SN38 released
from MNP.
Loading content of SN38 on Fe/Fe3O4
nanoparticles
The release of SN38 from the nanoparticles was carried out
under basic conditions (pH 12) at elevated temperature (95 °C)
in aqueous solution. Nanoparticles were removed by centrifuga-
tion at 8000 rpm, and free SN38 was extracted with DCM/
methanol 4/1 solution three times after adjustment of the pH
value of the supernatant to 3.0. Upon removal of the solvent, the
obtained SN38 was redissolved in 10 mL stock solution of
DCM/methanol 4/1 containing 70 μg/mL of anthracene. HPLC
analysis demonstrated that SN38 and anthracene were nicely
separated, with a retention time for SN38 of 7.581 min, and a
retention time for anthracene of 16.749 min (Supporting Infor-
mation File 1, Figure S3). SN38 standard solutions in the
concentration range from 2.13 to 51.10 μg/mL were prepared in
the same stock solution. A HPLC calibration curve for SN38
concentration versus relative peak area was constructed
(Supporting Information File 1, Figure S4). By fitting the rela-
tive peak area with this calibration curve, the loading content of
SN38 on the Fe/Fe3O4 nanoparticles was calculated to be
26 ± 3 mg/g.
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Figure 5: Double-stable Mo/Ma loaded with MNP-SN38 320 g/mL(medium). a: Prussian blue staining and counter stained by nuclear fast red 20×; b:
40×; c: control double-stable Mo/Ma Prussian blue stained and counter stained by nuclear fast red 20× (all images were taken in bright field).
AMF heating of MNP-SN38
Alternating magnetic field (AMF) heating of the SN38-loaded
Fe/Fe3O4 in a low strength and frequency magnetic field gener-
ated by an alternating current, demonstrated the superior
heating ability of the nanoparticles. Within five minutes, a
temperature increase of more than 30 °C was achieved when
exposing a dispersion of 2.0 mg nanoparticles in 2.0 mL of
water to the alternating magnetic field (Supporting Information
File 1, Figure S5). The specific absorption rate (SAR) is calcu-
lated to be 522 ± 40 W/g. We propose that the excellent heating
capacity of magnetic nanoparticles is due to the presence of the
Fe(0) core in this core/shell nanostructure, because Fe(0) has
the highest saturation magnetization per unit mass among all the
metal elements (σs = 218 Am2·kg−1 at 293 K) [52]. The heating
caused by ultrasmall magnetic nanoparticles in an alternating
magnetic field is due to the relaxation loss. Relaxation loss may
be either Neel or Brownian. In Neel relaxation, the nanoparti-
cles do not move, but the direction of magnetization inside the
particles rotates. In Brownian relaxation, the whole particle
rotates against resistance due to the viscosity of the surrounding
medium. For the localized magnetic hyperthermia application
using our core/shell MNP-SN38 nanoplatform, we suggest that
the heat generation is contributed by a combination of both Neel
relaxation loss and Brownian relaxation loss [29]. The superior
heating capacity of our nanoparticles permits both lower
concentrations and shorter AMF exposure times during
magnetic hyperthermia treatment.
Loading and toxicity of MNP-SN38 on cells
We selected tumor-homing cells, double-stable Mo/Ma as a
model cell to test the loading and toxicity of these nanoparti-
cles. To determine the optimal loading of MNP-SN38, first the
toxicity of MNP-SN38 for the double-stable Mo/Ma was deter-
mined. Different concentrations of nanoparticles were taken up
by double-stable Mo/Ma cells over 24 h; the nanoparticle-
concentration ranged from 0 to 320 μg/mL MNP-SN38 in fresh
medium. After 24 h, the inhibition of cell proliferation was
Figure 4: Toxicity of MNP-SN38 on double stable Mo/Ma after 24 h of
loading; the MTT assay was performed for cell viability, and cell
viability of 100% is considered in the case of the control group.
measured by using the MTT assay (Figure 4). We found only
20% of inhibition of cell proliferation at 160 μg/mL. Our aim is
the loading of high payloads onto each delivery cell without
causing a high level of necrosis or apoptosis of the delivery
cells. Even a loading of 320 μg/mL of nanoparticles in the
medium inhibits only 50% of the cell proliferation. We are also
interested in the long term toxicity without activating the
prodrug and changing cell morphology after loading. We have
found that these nanoparticles showed no further toxicity even
after five days (Figure 5). The successful loading of MNP-SN38
was confirmed by Prussian blue staining [53]. Nanoparticle-
loaded cells feature blue dots, indicating the presence of iron. In
contrast, no blue dots were observed in control cells. Moreover,
after loading into the Mo/Ma cells, nanoparticles remained
separated even after five days. This demonstrated the robust
stability of the MNP-SN38 platform under physiological condi-
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tions, which is highly desired for a cell-based delivery system.
We have established that when Mo/Ma cells are used as
carriers, the tumor-homing process takes about one day. Their
robust stability will ensure the integrity of the MNPs after
delivery to the tumor site.
The uptake efficiency of MNP-SN38 platform by the double-
stable Mo/Ma was determined by flow cytometry. Different
concentrations of nanoparticles were loaded into the cells over
24 h, by using nanoparticle concentrations between 0 and
320 μg/mL in culture medium. After 24 h of loading, the cells
were washed three times with 1× PBS, lifted and analyzed by
flow cytometry. The “side scatter” function was used to deter-
mine the loading of nanoparticles in the cells and compared to
the “side scatter” of control cells (Figure 6). The uptake of
nanoparticles by Mo/Ma cells correlates with the amount of
nanoparticles loaded in their culturing medium, indicating that
the MNP-SN38 platform can be easily loaded in the delivery
cells in defined concentrations. The iron content of the nanopar-
ticles, as well as the concentration of iron in nanoparticle-
loaded cells was determined by using the ferrozine assay. A
mass of 1.0 mg of nanoparticles contained 0.427 mg of iron,
indicating that this amount of iron would be high enough for
alternating magnetic field hyperthermia in combination with
chemotherapy [54]. The MTT assay indicated that 8 pg of iron
can be easily loaded in each cell (20% inhibition of cell prolif-
eration) (Figure 4 and Figure 7). It is even possible to load
16 pg of iron in each cell (with 50% inhibition of cell prolifera-
tion) indicating that 2.1·10−15 mol of SN38 can be easily loaded
in each delivery cell.
Figure 6: Flow cytometry of MNP-SN38 loaded double-stable Mo/Ma
after 24 h. Side scatter was used to measure loading of nanoparticles
in cells. Concentrations of 0–320 µg/mL of MNP-SN38 were loaded
and allowed 24 h for loading.
To test the release of SN38 by the self-contained Tet-On
Advanced system, Mo/Ma cells were plated in a 24-well plate at
a density of 300,000 cm−2, and incubated overnight at 37 °C to
Figure 7: Iron concentration per double-stable Mo/Ma cell loaded with
different concentrations of MNP-SN38.
become 70% confluent. The next day, the medium was
removed, and wells of the plate were divided into three groups
evenly, each group containing eight replications. SN38-loaded
Fe/Fe3O4 nanoparticles in fresh medium at 80, 160, and
320 µg/mL were added to group 1, group 2 and group 3, res-
pectively. After incubation for 24 h, the medium was removed
and the cells were washed with fresh Mo/Ma medium. Then
1 μg/mL doxycycline containing medium was added to half of
the replications in each group, and to the other half only fresh
medium was added. After incubation for three days, the
medium in each group with and without doxycycline was
collected and centrifuged for 5 min at 1000 rpm to remove cell
debris. The aqueous phases were extracted with methylene
chloride three times, and the combined methylene chloride
phases were dried over anhydrous Na2SO4. After concentration
of the volume to 500 μL, each sample was subjected to HPLC
analysis. No SN38 was observed by HPLC in the control
groups; in contrast, a significant peak corresponding to the
SN38 retention time was visible in HPLC for groups with added
doxycycline (Supporting Information File 1, Figure S6), indi-
cating the successful release of SN38 by the Tet-On Advanced
system.
Conclusion
We have developed a nanoplatform that will potentially permit
the treatment of cancer by a combination of magnetic hyper-
thermia and chemotherapy (thermochemotherapy) after targeted
delivery by double-stable RAW264.7 monocyte/macrophage-
like cells (Mo/Ma). A carboxylesterase-cleavable irinotecan-
like SN38 prodrug was synthesized and attached to Fe/Fe3O4
magnetic nanoparticles. The prodrug concentration that was
chemisorbed via dopamine-anchors to the Fe3O4 outer layer of
the core/shell nanoparticles was 26 ± 3 mg/g. The MNP-SN38
nanoplatform showed efficient heating ability in an alternating
magnetic field (SAR = 522 ± 40 W/g). In accordance with the
design of the dopamine-anchored SN38 prodrug, the nanoplat-
form demonstrated minimal cytoxicity for tumor-homing
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Scheme 3: RAW264.7 cell (monocyte/macrophage) delivered thermochemotherapy.
Mo/Ma cells. These cells feature a Tet-On Advanced system for
intracellular carboxylesterase (InCE) expression. Upon add-
ition of doxycycline, SN38 was released from the nanoplatform,
as evidenced by HPLC analysis. Therefore, this nanoplatform
can be potentially used as a multipurpose agent in cancer
therapy through highly localized magnetic hyperthermia and
triggered release/activation of the chemotherapeutic drug SN38
at the cancer site. Using the synergy between targeted
chemotherapy and hyperthermia will make cell-delivered anti-
cancer treatment a viable option. Scheme 3 summarizes this
approach to Mo/Ma-cell-delivered thermochemotherapy.
Supporting Information
Detailed experimental procedures, spectroscopic
characterizations, DLS and zeta-potential measurements, as
well as HPLC analysis are provided.
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